Zoetis Inc. $ZTS Shares Bought by Berkeley Inc

Berkeley Inc grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 20.1% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 52,317 shares of the company’s stock after buying an additional 8,772 shares during the quarter. Zoetis makes up 2.5% of Berkeley Inc’s holdings, making the stock its 13th biggest holding. Berkeley Inc’s holdings in Zoetis were worth $7,655,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Zoetis by 0.8% during the second quarter. Vanguard Group Inc. now owns 41,886,987 shares of the company’s stock worth $6,532,276,000 after acquiring an additional 330,823 shares during the last quarter. Geode Capital Management LLC increased its position in Zoetis by 0.9% during the 2nd quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock worth $1,721,356,000 after purchasing an additional 95,294 shares in the last quarter. Norges Bank acquired a new stake in Zoetis during the 2nd quarter worth approximately $809,491,000. Brown Advisory Inc. raised its holdings in Zoetis by 5.7% in the second quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock valued at $726,629,000 after buying an additional 250,829 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Zoetis by 113.0% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock worth $586,671,000 after buying an additional 1,995,491 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 1.1%

Shares of NYSE:ZTS opened at $123.24 on Wednesday. The company’s fifty day moving average is $123.37 and its two-hundred day moving average is $138.85. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. Zoetis Inc. has a 1-year low of $115.25 and a 1-year high of $177.40. The stock has a market capitalization of $54.31 billion, a price-to-earnings ratio of 20.75, a price-to-earnings-growth ratio of 2.53 and a beta of 0.97.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The company’s revenue for the quarter was up .5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Tuesday, January 20th. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s payout ratio is currently 33.67%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of research reports. UBS Group cut their target price on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. HSBC set a $140.00 price objective on Zoetis in a research report on Wednesday, December 10th. The Goldman Sachs Group raised Zoetis to a “buy” rating in a research report on Monday, December 15th. Weiss Ratings upgraded Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 13th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Six analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $160.18.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.